Covid-19 mRNA vaccines go head-to-head: Which has ‘fridge’ advantage and which CMOs stand to benefit?

Covid-19
Pfizer and BioNTech announced that their vaccine candidate showed 95% efficacy in a Phase III trial of more than 43,000 participants with and without prior SARS-CoV-2 infection. Credit: Shutterstock.